OPTN (OptiNose, Inc.) Utang jangka cendhak marang modal

OptiNose, Inc. (OPTN) management is striving to achieve profitability, which allows the current 0.00 metric to be tracked through the asset's market dynamics. The firm's profitability relies on the commercial success of XHANCE and the drug's recognition by insurance companies. Meanwhile, the company is optimizing expenses by outsourcing drug manufacturing, clinical research, and distribution to third-party contractors.

This indicator measures the proportion of short-term liabilities relative to equity, allowing for an assessment of liquidity gap risks by comparing current debt with the base value of assets. By analyzing changes in the short-term debt-to-equity ratio, an investor can determine the financial stability of OptiNose, Inc. (OPTN) as it scales its nasal technologies and licenses drug delivery systems to third-party pharmaceutical partners.